Zhang Xiao-Yu, Wang Yan-Ping, Lin Li-Kai, Shang Hong-Cai, Wang Yong-Yan
Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2017 Aug;42(16):3229-3232. doi: 10.19540/j.cnki.cjcmm.20170623.007.
As an important representative of modern Chinese medicine, traditional Chinese medicine (TCM) injzection has become an indispensable part of the Chinese medicine industry. However, its development is now restricted by the bottleneck of insufficient core competitiveness, low-level research and production, even injection quality and the safe use are not guaranteed. Thus, it is urgent to reevaluate post-marketing TCM injection generally and to make secondary development. Under current circumstances, taking major brands which have good clinical and market foundation, as well as research value, as the main subject of cultivation and evaluation is an important approach to innovative development of TCM injection industry. Unlike oral proprietary Chinese medicine, the cultivatation of major brands of TCM injection needs higher technical support, quality standards and more timely feedback. Therefore, a post-market integral evaluation system adaptive to TCM injection is required. This article discussed some key points on the construction of a post-market integral evaluation system of TCM injection in three levels: optimizing evaluation methods, building synergistic innovation platforms which combine the medical research institutions and pharmaceutical enterprises, and finally constructing the integral evaluation system. A "five to one" structure has been proposed to enhance TCM injection effectiveness, safety and adaptability on the whole, which are from the following aspects: mechanism research, clinical evidence validation, literature information mining, sustainable development of resources and industrialization operation.
中药注射剂作为现代中药的重要代表,已成为中药产业不可或缺的一部分。然而,其发展目前受到核心竞争力不足、研发生产水平低的瓶颈制约,甚至注射剂质量和安全使用都无法得到保障。因此,迫切需要对上市后中药注射剂进行全面重新评估并进行二次开发。在当前情况下,以具有良好临床和市场基础以及研究价值的大品牌作为培育和评价的主要对象,是中药注射剂产业创新发展的重要途径。与口服中成药不同,中药注射剂大品牌的培育需要更高的技术支持、质量标准和更及时的反馈。因此,需要一个适应中药注射剂的上市后综合评价体系。本文从优化评价方法、构建医学研究机构与制药企业相结合的协同创新平台、最终构建综合评价体系三个层面探讨了中药注射剂上市后综合评价体系建设的一些要点。提出了一种“五位一体”结构,从作用机制研究、临床证据验证、文献信息挖掘、资源可持续发展和产业化运营等方面全面提高中药注射剂的有效性、安全性和适应性。